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Abstract 
The objective of this study was to evaluate the potential of the structurally-related 
aliphatic isothiocyanates erucin and sulforaphane to modulate the pulmonary 
carcinogen-metabolising enzyme systems in rat lung, a target organ of their 
chemopreventive activity. Precision-cut rat lung slices were prepared and incubated 
for 24 hours with a range of concentrations of either erucin or sulforaphane, up to 50 
μM. Neither compound modulated the O-deethylation of ethoxyresorufin whereas 
they elevated markedly CYP1A1 and, to a lesser extent, CYP1B1 apoprotein levels. 
Neither compound influenced the O-depentylation of pentoxyresorufin or CYP2B 
apoprotein levels, but sulforaphane caused a modest increase in CYP3A2 apoprotein 
levels. Pulmonary quinone reductase activity, monitored using 3-(4,-5-
dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide as substrate, was markedly up-
regulated by both compounds and was paralleled by a similar rise in protein levels. 
Both compounds increased cytosolic glutathione S-transferase activity, measured 
using 1-chloro-2,4-dinitrobenzene as the accepting substrate; a modest rise was seen 
in GSTα protein levels, determined immunologically, whereas GSTπ levels were un-
affected by the same treatment. Finally, both erucin and sulforaphane increased total 
glutathione concentration in lung cytosol. It is concluded that these aliphatic 
isothiocyanates have the potential to antagonise the carcinogenicity of pulmonary 
carcinogens by stimulating the in situ detoxication of their DNA-binding genotoxic 
metabolites. 
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Introduction 
Numerous epidemiological studies have established that dietary habits play a pivotal 
role in the aetiology and progression of human diseases including cancer [1]. A large 
number of dietary phytochemicals have been recognised with potential 
chemopreventive activity, and in laboratory studies they could antagonise the 
carcinogenicity of chemicals in animal models. One of the most extensively studied 
classes of chemopreventive phytochemicals is the isothiocyanates. These are 
encountered in cruciferous vegetables where they occur in the form of glucosinolates 
but are released following exposure to the enzyme myrosinase (β-thioglucoside 
glucohydrolase) that comes into contact with these compounds during the harvesting, 
chopping and mastication of these vegetables [2] Moreover, glucosinolates that 
progress intact to the human intestine intact may be metabolised by microbial 
myrosinases, further contributing to the release of isothiocyanates [3]. 
 Several studies reported that high intake of isothiocyanates in the diet was 
associated with a reduced risk of lung cancer in humans [4, 5]. In laboratory studies, a 
major target organ of isothiocyanates is the lung, where many isothiocyanates 
suppressed tumourigenesis in mouse and rat induced by exposure to pulmonary 
carcinogens. For example, in A/J mice, the aromatic isothiocyanates benzyl and 
phenethyl isothiocyanate decreased the tumour yield in animals exposed to the 
carcinogens benzo[a]pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) [6]. In the same mouse strain, benzyl isothiocyanate was an effective inhibitor 
of lung tumourigenesis  induced by 5-methylchrysene, dibenz[a,h]anthracene, 
benzo[a]pyrene and diethylnitrosamine  [7, 8]. Phenethyl isothiocyanate anatagonised 
the carcinogenicity of the tobacco carcinogen NNK and inhibited DNA-adduct 
formation in rat [9]. Finally, the malignant progression of lung adenomas induced by 
 4
a mixture of benzo[a]pyrene and NNK was inhibited by sulforaphane (1-
isothiocyanato-4-(methylsulphinyl) butane) and phenethyl isothiocyanate [10].  
A major mechanism through which isothiocyanates exert their 
chemopreventive effect is by modulating the enzymes involved in the metabolism of 
chemical carcinogens, altering the balance of activation/deactivation so as to favour 
the latter. Isothiocyanates are believed to limit the production of DNA-binding 
electrophilic metabolites by inhibiting their cytochrome P450-mediated generation on 
one hand, and stimulating their detoxication on the other. Indeed, a number of 
isothiocyanates have been shown to influence hepatic cytochrome P450 expression as 
well as phase II enzyme systems such as quinone reductase and glutathione S-
transferase [11]. In contrast to the liver, very few studies have been undertaken in the 
lung, despite the fact that this a major target organ for the chemopreventive activity of 
isothiocyanates. Moreover, the limited studies carried out have identified tissue 
differences in the response of lung and liver to isothiocyanates. Phenethyl 
isothiocyanate up-regulated markedly quinone reductase in the liver but not in the 
lung of rats [12, 13].  
Consequently, we investigated the potential of sulforaphane and erucin (1-
isothiocyanato-4-(methylthio)-butane), a structurally related isothiocyanate present in 
rocket salad, to modulate carcinogen-metabolising enzyme systems in rat lung; it has 
already been documented that these isothiocyanates modulate these enzyme systems 
in rat liver [14]. The studies reported here were conducted in vitro utilising precision-
cut lung slices [15] The principal advantages of this in vitro system are that it 
maintains tissue architecture and cell-cell communication, and allows the facile use of 
a wide range of concentrations of chemicals, that would otherwise necessitate large 
animal numbers for commensurate in vivo studies [16]. It is particularly suited to the 
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lung, a heterogeneous tissue composed of many different cell types that differ 
markedly in their carcinogen-metabolising enzyme profile [17]. Studies emanating 
from our laboratory have established that precision-cut slices are an appropriate 
system for use in evaluating the potential of xenobiotics to modulate cytochrome 
P450 and phase II activities in the lung [18].  
 
Materials and methods 
Materials  
Sulforaphane and erucin (LKT Laboratories, Minnesota, USA), NADPH, 
ethoxyresorufin, pentoxyresorufin, resorufin, 1-chloro-2,4-dinitrobenzene (CDNB), 
glutathione reductase, peroxidase-linked anti-rabbit and anti-goat antibodies raised in 
rabbits (Sigma Co. Ltd., Poole, Dorset, UK)  were all purchased. Rat anti-CYP1A1, 
recognising both CYP1A1 and CYP1A2, anti-CYP1B1, anti-CYP2B and anti-
CYP3A2 antibodies were obtained from BD Biochemicals (Oxford, UK); antibodies 
to human  GST P1-1, A1-1 and M1-1 (Calbiochem, Merck, UK) and antibody to 
human quinone reductase (abcam Cambridge, UK) were similarly purchased. 
 
Preparation and incubation of slices 
Male Wistar albino rats (about 180g) were obtained from B&K Universal Ltd (Hull, 
East Yorkshire, UK). The animals were housed at 22 ± 2 °C, 30-40 % relative 
humidity, in an alternating 12-hr light:dark cycle with light onset at 07.00 hr. 
Precision-cut rat lung slices were prepared as previously described [15]. Briefly, lungs 
were perfused intratracheally with agarose (0.75% v/w) at 37 °C. Agar was allowed to 
solidify, and lung slices (600 m) were prepared from cylindrical cores (8 mm) using 
a Krumdieck tissue slicer (Alabama Research and Development Corporation, 
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Munsford, AL, USA). The multiwell plate procedure, using 12-well culture plates, 
was used to culture the slices. The culture medium was essentially that described by 
Lake et al [19], and one slice was placed in each well, in 1.5 ml of culture medium. 
Slices were initially pre-incubated for 60 min in order to slough off any dead cells due 
to slicing, before being transferred to fresh medium and incubated for a period of 24 
hours in the presence of a range of concentrations of sulforaphane or erucin on a 
reciprocating plate shaker housed in a humidified incubator, at a temperature of 37 ºC 
and under an atmosphere of 95 % air/5% CO2.  
 
Enzyme assays 
 At the end of incubation, slices were removed from the medium, homogenised and 
post-mitochondrial fractions were prepared by differential centrifugation and stored at 
-80°C until use. When required, samples were thawed and resolved to microsomal 
and cytosolic fractions by centrifugation (105 000g x 1 hour). The dealkylations of 
ethoxy- [20] and pentoxyresorufin [21] were determined using the microsomal 
fraction. The following assays were performed using the cytosol; quinone reductase 
using MTT [3-(4,-5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide] as 
substrate [22], glutathione S-transferase activity using CDNB as accepting substrate 
[23], and total glutathione [24]. Protein concentration was determined in both 
fractions using bovine serum albumin as standard [25]. Finally, in order to determine 
changes in enzyme protein expression, pooled pulmonary microsomal and cytosolic 
proteins were resolved by electrophoresis and incubated with the primary antibody 
and the corresponding peroxidase-linked secondary antibody. Molecular markers 
were run concurrently in all cases. Immunoblots were quantitated by densitometry 
using the GeneTool software (Syngene Corporation, Cambridge, UK).  
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Lactate dehydrogenase (LDH) release from the lung slices into the incubation 
medium was used as an index of cytotoxicity. The LDH concentration was measured 
employing a cytotoxicity detection kit plus (Roche Diagnostics, Mannheim, 
Germany), using three slices per concentration of isothiocyanate. On completion of a 
24-h incubation, the culture medium was aspirated and the tissue slices were each 
homogenised in 1.5 ml of phosphate buffered saline (PBS), pH 7.4. The media and 
homogenates were centrifuged at 2000 x g for 5 min at 4˚C using a bench centrifuge. 
Duplicate aliquots (0.1 ml) were used for LDH analysis according to the 
manufacturer’s instructions.  
 
Statistical evaluation 
Statistical evaluation was carried out using the Student’s t-test. 
 
Results  
Neither erucin (Figure 1) nor sulforaphane (Figure 2) influenced the O-dealkylations 
of ethoxy- and pentoxyresorufin in rat lung slices, except for a decrease that occurred 
only at the highest concentrations. Immunological determination of apoprotein levels 
indicated a concentration-dependent increase in CYP1A1 apoprotein levels brought 
about by both isothiocyanates, which diminished at the highest concentrations (Figure 
3). A similar, but less pronounced, rise was also observed in CYP1B1 apoprotein 
levels following exposure of lung slices to these isothiocyanates. A modest rise in 
CYP3A2 proteins was also noted in the case of sulforaphane but not erucin; neither 
isothiocyanate influenced CYP2B apoprotein levels. 
 Erucin and sulforaphane elevated, in a concentration-dependent manner, 
quinone reductase activity when incubated with lung slices for 24 hours; both 
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compounds also brought about a rise in glutathione S-transferase activity (Figures 1 
and 2).  Similarly, both compounds elevated total glutathione levels with sulforaphane 
being more effective. Quinone reductase protein levels were trebled by treatment of 
lung slices with both isothiocyanates (Figure 4). Finally, the isothiocyanates 
moderately elevated GSTα protein levels and slightly GSTμ levels, with no change in 
GST (Figure 4).   
Lung slice viability was assessed using as biomarker the secretion of lactate 
dehydrogenase in to the culture medium. Sulforaphane displayed no toxicity up to a 
concentration of 10 μM but a concentration-dependent increase in lactate 
dehydrogenase secretion was noted at higher concentrations (Figure 5). Erucin 
displayed toxicity only at the 50 and 100 μM concentrations. 
 
Discussion 
Lung is a major target tissue for many chemical carcinogens of human relevance, 
including polycyclic aromatic hydrocarbons, heterocyclic amines and nitrosamines, 
all of which are present in tobacco, albeit at different levels [26]. These carcinogens 
are indirect-acting so that in order to elicit their carcinogenicity they must first be 
metabolically converted to DNA-binding species, and this process is largely catalysed 
by cytochromes P450 [27]. Such bioactivation can take place in situ, but there is also 
experimental evidence to support the view that reactive intermediates generated in the 
liver, the principal site of bioactivation, may be transported to extrahepatic tissues 
although the underlying mechanism(s) remain elusive [28, 29]. A number of studies 
have linked pulmonary CYP1 activity to human cancer incidence, denoting the 
importance of in situ metabolism. For example, a very significant correlation has been 
reported between pulmonary levels of CYP1A1 and DNA adduct levels with the 
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tobacco-derived polycyclic aromatic hydrocarbons [30]. Among smokers, those who 
develop tumours display high CYP1A1 activity in the lung [31]. Moreover, the 
bioactivation of polycyclic aromatic hydrocarbons by CYP1A1 appears to occur in 
the same part of the airways and in the same cell types in which peripheral 
carcinomas are observed [32]. However, the availability of DNA-binding 
intermediates is not solely dependent on their rate of generation, as these may be 
detoxified by enzyme systems such as quinone reductase and the glutathione S-
transferases. Thus, an effective chemopreventive agent would be a chemical that 
suppresses the cytochrome P450-catalysed formation and/or increases phase II 
detoxication of the DNA-binding carcinogen metabolites. Consequently, we 
investigated the ability of erucin and sulforaphane, two naturally-occurring 
isothiocyanates, to modulate the profile of cytochrome P450 and phase II activities in 
rat lung. 
 When incubated with precision-cut rat lung slices, both erucin and 
sulforaphane modulated cytochrome P450 expression, but in an isoform-specific 
manner. Both isothiocyanates led to a marked elevation of CYP1A1 and, to a lesser 
extent, CYP1B1 apoprotein levels, whereas CYP2B was unaffected and CYP3A2 was 
moderately up-regulated only by sulforaphane. A similar qualitative picture was 
obtained in liver slices incubated with these isothiocyanates under identical conditions 
[14]. Despite the marked rise in CYP1A1 expression, no commensurate increase in 
activity, as exemplified by the O-deethylation of ethoxyresorufin, was observed. We 
have already established in studies conducted in rat liver microsomal preparations that 
both erucin and sulforaphane are effective mechanism-based inhibitors of this 
cytochrome P450 enzyme [33], and most likely the same mechanism is responsible 
for the lack of increase in CYP1A1 activity in the lung. The metabolites of 
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isothiocyanates responsible for this inhibition of activity are believed to be 
isocyanates that are generated by cytochrome P450-mediated desulphuration [34]. 
Clearly the lung, despite its much lower concentration of cytochrome P450 compared 
with the liver, is capable of metabolically converting erucin and sulforaphane to 
products that react with and inactivate the enzyme. 
 The effects of these isothiocyanates on carcinogen-metabolising enzymes are 
not confined to the cytochrome P450 enzyme system as changes were also observed 
in phase II activities. Both compounds enhanced quinone reductase activity that was 
paralleled by a rise in protein levels indicating that increased enzyme availability is 
responsible for the increased activity. As this enzyme system is responsible for the 
detoxification of quinones, it may be inferred that these isothiocyanates have the 
potential to antagonise the carcinogenicity of polycyclic aromatic hydrocarbons in the 
lung through such a mechanism. In addition to quinones, polycyclic aromatic 
hydrocarbons are bioactivated to primary and dihydrodiol epoxides which are 
electrophiles that readily interact covalently with DNA [35]. These intermediates may 
be neutralised by conjugation with glutathione catalysed by the cytosolic glutathione 
S-transferases. Both erucin and sulforaphane stimulated glutathione S-transferase 
activity when incubated with precision-cut lung slices, as previously observed in liver 
slices [36]. Glutathione S-transferase activity was monitored using CDNB, an 
accepting substrate for a number of the cytosolic transferases [37]. Immunoblot 
analysis revealed that the effects of these isothiocyanates on the glutathione S-
transferase system are isoform-specific, in that GSTα was clearly elevated with only a 
marginal rise in GSTμ and no effect in GST. A similar induction profile was 
obtained when liver slices were incubated with erucin and sulforaphane under 
identical conditions [36]. As observed in liver slices [36], an increase in total 
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glutathione levels was manifested by both compounds, this effect is probably of 
greater importance in the lung where basal levels of glutathione are much lower. An 
increase in -glutamylcysteine synthetase, the rate-limiting enzyme in glutathione 
biosynthesis, is believed to be the responsible mechanism [2].  
At the highest concentrations of the isothiocyanates (>25μM), the 
dealkylations of the two alkoxyresorufins dropped below control levels, most likely 
reflecting decreased viability of the lung slices as exemplified by increased leakage of 
lactate dehydrogenase. As exemplified by the leakage of lactate dehydrogenase, 
erucin appears to be less toxic than sulforaphane to rat lung slices. It should be 
emphasised that such concentrations are unlikely to be achieved following single 
dietary intake of these isothiocyanates; when rats were treated with a single dose of 
sulforaphane, simulating human intake, the maximum plasma concentrations achieved 
were <0.3 μM [38]. However, plasma concentrations of isothiocyanates are likely to 
be higher in individuals consuming cruciferous vegetables daily or take nutritional 
supplements of isothiocyanates. Although this concentration is lower than the lowest 
employed in the current study (1 μM), in animal anticarcinogenicity studies, not only 
are these isothiocyanates given at much higher doses, but also daily for almost the 
entire life span of the animals, so that the steady-state state plasma isothiocyanate 
concentrations in these animals are expected to be orders of magnitude higher. 
Therefore, the wide range of concentrations we employed in our studies (1-50 μM) 
represents the lowest plasma concentration and the maximum concentration tolerated 
by the slices. As far as human intake is concerned, a single intake of 100g of broccoli, 
a relatively modest amount, achieved a mean peak concentration of nearly 1μM [39]. 
However, plasma concentrations of isothiocyanates are likely to be higher in 
individuals consuming cruciferous vegetables daily or take nutritional supplements of 
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isothiocyanates. Finally, it is pertinent to point out that recent work suggests that GST 
phenotype may be a determining factor in plasma concentrations, since conjugation 
with glutathione is the primary route of metabolism of isothiocyanates, so that 
generalisations about plasma levels could be misleading [40]. 
 In conclusion, both erucin and sulforaphane influence the activity of 
carcinogen-metabolising enzymes in rat lung slices to a similar extent. As erucin is a 
major metabolite of sulforaphane, at least in rat [41, 42], it is conceivable that it 
contributes to its chemopreventive effects. No major tissue differences between lung 
and liver slices [14, 36] could be discerned in their response to the two 
isothiocyanates. The most marked effects manifested by sulforaphane and erucin were 
enhanced quinone reductase and glutathione S-transferase activity, and this 
mechanism may be largely responsible for the documented chemopreventive effect of 
isothiocyanates in the lung of animals exposed to polycyclic aromatic hydrocarbons. 
Finally, the current study further highlights the suitability of the precision-cut tissue 
system in evaluating the potential of chemicals to modulate these enzyme systems. 
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Figure legends 
 
 
Figure 1: Effect of erucin on cytochrome P450, phase II enzyme activities and 
glutathione concentrations in rat lung slices.  
 
Lung slices were incubated in modified RPMI 1640 culture medium containing erucin 
(0 to 50µM) for 24 h. Values represent the mean ± SD where n=3, each replicate 
comprising up to 12 slices.  EROD, ethoxyresorufin O-deethylase; PROD, 
pentoxyresorufin O-depentylase; QR, quinone reductase; GST, glutathione S-
transferase.  *, P<0.05, **, P<0.01.  
 
Figure 2: Effect of sulforaphane on cytochrome P450, phase II enzyme activities 
and glutathione concentrations in rat lung slices.  
 
Lung slices were incubated in modified RPMI 1640 culture medium containing 
sulforaphane (0 to 50µM) for 24 h. Values represent the mean ± SD where n=3, each 
replicate comprising up to 12 slices.  EROD, ethoxyresorufin O-deethylase; PROD, 
pentoxyresorufin O-depentylase; QR, quinone reductase; GST, glutathione S-
transferase.  *, P<0.05, **, P<0.01.  
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Figure 3: Modulation by erucin (A) and sulforaphane (B) of pulmonary 
cytochrome P450 protein expression.  
 
Lung slices were incubated in modified RPMI 1640 culture medium containing either 
erucin or sulforaphane (0 to 50 µM) for 24h. Pulmonary microsomal proteins were 
resolved by 10 % (w/v) SDS-PAGE and then transferred electrophoretically to 
Hybond-P polyvinylidene difluoride membranes. Immunoblot analysis was carried 
out using rat antibodies to cytochrome P450 proteins, followed by the appropriate 
peroxidase-labelled secondary antibody. Each lane was loaded with 10 (CYP2B1, and 
CYP3A2) or 40 (CYP1A and CYP1B1) µg of total protein. Molecular markers were 
run concurrently to aid band identification. The values in italics show optical density 
percentage of each band relative to control 
 
Figure 4: Modulation by erucin (A) and sulforaphane (B) of pulmonary phase II 
enzyme protein expression.  
 
Lung slices were incubated in modified RPMI 1640 culture medium containing either 
erucin or sulforaphane (0 to 50 µM) for 24h. Pulmonary microsomal proteins were 
resolved by 10 % (w/v) SDS-PAGE and then transferred electrophoretically to 
Hybond-P polyvinylidene difluoride membranes. Immunoblot analysis was carried 
out using rat antibodies to phase II enzymes, followed by the appropriate peroxidase-
labelled secondary antibody. Each lane was loaded with 10 (GSTπ) or 20 (GSTa, 
GSTµ and QR) µg of total protein. Molecular markers were run concurrently to aid 
band identification. The values in italics show optical density percentage of each band 
relative to control. QR, quinone reductase; GST, glutathione S-transferase. 
 
Figure 5: Lactate dehydrogenase (LDH) leakage from rat lung slices incubated 
with erucin or sulforaphane.  
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LDH leakage was determined following 24-h incubation of lung slices in modified 
RPMI 1640 containing a range of concentrations (0 to 100 µM) of either erucin or 
sulforaphane. LDH release is expressed as percentage of total LDH, i.e. the sum of the 
concentration retained in the slice plus the concentration leaked. Values are presented 
as mean ± SD of duplicate measurements from each of three slices per concentration. 
*, P<0.05, **, P<0.01 and ***, P<0.001.   
 
 
